2nd Open Scientific EIP Symposium Immunogenicity of Biopharmaceuticals
17th — 19th November 2009
Leiden, the Netherlands
Downloads
Opening
Proposed Mechanisms for Aggregate Induced Immunogenicity Bachmann (Cytos biotechnology)
The Effects of Induced Aggregation of IgG and Insulin Preparations on In Vitro T Cell Stimulation Baker (Antitope)
Large-scale T cell Epitope Discovery tools Soren Buus (University of Copenhagen)
Screening & Confirmatory Cut-Points - Brief Overview & Answers to some FAQs V. Devanarayan (Abbott Laboratories, USA)
Correlation of ADA with Clinical and Non-Clinical Study Endpoints: A Case Study and Lessons Learned Deborah Finco (Pfizer, USA)
Heparin-induced Thrombocytopenia the most frequent drug induced immune response Andreas Greinacher (Universität Greifswald, Germany)
Selective removal of B cell epitopes from bacterial proteins: Exemplified by the generation of a novel C5a receptor antagonist for treatment of acute inflammation Erika Gustafsson (Alligator Bioscience)
Workshop presentation: Development and application of Bioinformatics methods Ole Lund
Prediction of immunogenicity of peptide drugs using bioinformatics Ole Lund
A role for complement and immune complexes in immune responses to therapeutic antibodies? Claus H. Nielsen (Copenhagen University Hospital, Denmark)
Immunogenicity of recombinant human therapeutics characterization of the underlying immune response Melody Sauerborn (Universiteit Utrecht)
Recommendations for immunoassay methods used for the detection of host antibodies against biotechnology products Gopi Shankar (Centocor, USA)
Structural Aspects of Immunogenicity: Aggregates Ronald Smulders (Schering-Plough)
Immunogenicity of biotherapeutics Stas (Algonomics)
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell-Bassed Assay Platform Technology Michael G Tovey (Institut André Lwoff, France)
Antibodies and immunological memory induced by aggregated interferon beta in a transgenic immune tolerant mouse model Miranda van Beers (UIPS Utrecht Institute for Pharmaceutical Sciences)
Immunogenicity of therapeutic antibodies Clinical Significance Gertjan Wolbink (Jan van Breemen Instituut)
